NEW YORK (TheStreet) -- On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, was very excited about Regeneron's (REGN - Get Report) new cholesterol drug, Alirocumab.
The stock is breaking out, Cramer said, adding that Credit Suisse suggests it can go to $400 per share."It's a very big win for Regeneron. It could be a multi-billion market," he said. Turning to Conn's (CONN - Get Report) , Cramer noted that the stock is plummeting -- down over 30%. Management expressed concern that customers would not be paying Conn's the money it is owed. Investors want exposure to domestic retailers to protect themselves from geopolitical risks, Cramer said, but not all domestic retailers are created equal. He concluded that he is not a buyer of Conn's following the selloff, because a lot of investors still want to get out of the stock. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell Read More: 10 Most Affordable Cars Of 2014
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts